Board of Directors
Stanley C. Erck, Executive Chairman
Former President and Chief Executive Officer of Iomai Corporation
Gary C. Evans, Lead Director
Chairman and Chief Executive Officer and founder of Green Hunter Energy, Inc., Owner and co-founder, Wind Hunter, LLC, Retired Chairman, President and Chief Executive, Magnum Hunter Resources, Inc.
John Lambert
Former President of Chiron Vaccines, current director of J.G. Solutions Ltd.
John O. Marsh, Jr.
Distinguished Professor of Law, George Mason University, Former Secretary of the Army and U.S. Congressional Representative
Michael A. McManus, Jr.
President, Chief Executive Officer and Director, Misonix, Inc.
Rahul Singhvi, Sc.D.
President and Chief Executive Officer, Novavax, Inc.
Dr. Rajiv I. Modi
Managing Director, Cadila Pharmaceuticals
James F. Young, Ph.D.
Former President of Research and Development, MedImmune, Inc.
Richard Douglas, Ph.D.
Senior Vice President, Corporate Development, Genzyme Corporation
The chart below describes the structure of Novavax's Board of Directors and its committees.
| Audit Committee | Compensation Committee | Corporate Governance Committee | Finance Committee | ||||||
| Gary C. Evans | X | X | Chairman | Chairman | |||||
| John O. Marsh | X | Chairman | X | ||||||
| Michael A. McManus | Chairman | X | X | X | |||||
| Stanley Erck | X | ||||||||
| Rahul Singhvi | X | ||||||||
| James Young | X | X | |||||||
Stanley C. Erck, Executive Chairman
Executive Chairman of the Board of Directors of Novavax since February, 2010. From 2000-2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the Board of Directors of MacCyte and MdBio Foundation. He received his undergraduate degree from the University of Illinois and his Masters in Business Administration from the University of Chicago Graduate School of Business.
Gary C. Evans, Lead Director
Gary C. Evans is the Chairman and Chief Executive Officer and founder of GreenHunter Energy, Inc., an alternative energy company involved in wind, biofuels and biomass power production listed on the American Stock Exchange. Mr. Evans is also a principal in Global Hunter Holdings, L.P., the parent of Global Hunter Securities, LLC., entities active in both direct capital investments and investment banking activities for numerous high growth Chinese based enterprises.
During the prior twenty years until April 2005, Mr. Evans served as Chairman, President and Chief Executive Officer of Magnum Hunter Resources, inc. (a New York Stock Exchange listed company) and Chairman and Chief Executive Officer of all the Magnum Hunter subsidiaries since their formation or acquisition dating back to 1985. Mr. Evans founded the predecessor company, Hunter Resources, Inc., that was merged into and formed Magnum Hunter Resources Inc., until its merger with Cimarex Energy, Inc. (NYSDE: XEC) during 2005.
Mr. Evans currently serves as the Lead Director of Novavax, Inc., a NASDAQ listed pharmaceutical company. Mr. Evans serves as an Individual Trustee of TEL Offshore Trust, a NASDAQ listed oil and gas trust. Mr. Evans was recognized by Ernst & Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy Sector and was recently inducted into the World Hall of Fame for Ernst & Young Entrepreneurs.
↑ Back to Top
John Lambert
John Lambert served as President of Chiron Vaccines, a biopharmaceutical company, from 2001 to 2005. President, Aventis Pasteur MSD, a vaccine joint venture established between Aventis (now Sanofi) and Merck Vaccines, 1998 to 2000. Mr. Lambert is currently the Vice President of the Conseil d’Administration of Farmaprojects S.A. (Spain), Non-Executive Chairman of Cambridge Biostability Ltd. (U.K.), current director of J.G. Solutions Ltd and Non-Executive director of Acambis plc (U.K.) Mr. Lambert served as Executive Chairman for Novavax from 2007 until 2010 and continues to serve as a Director on the Board of Novavax, Inc., a NASDAQ listed pharmaceutical company.
John O. Marsh, Jr.
Co-Chair of Independent Review Group for Walter Reed Hospital and Bethesda Navy Medical Center since 2007. Visiting Professor, George Mason University Law School, since 2001. Visiting Professor, Virginia Military Institute, 1998. Interim Chief Executive Officer of Novavax from July 1996 to March 1997 and Chairman of the Board of Directors from July 1996 to February 1997. Secretary of the Army from 1981 to 1989. Counselor with Cabinet rank to the President of the United States from 1974 to 1977. Assistant for National Security Affairs to Vice President of the United States, 1974. Assistant Secretary of Defense from 1973 to 1974. U.S. Representative in Congress from 1963 to 1971.
Michael A. McManus, Jr.
President, Chief Executive Officer and Director of Misonix, Inc., a medical, scientific and industrial provider of ultrasonic and air pollution systems, since 1998. President and Chief Executive Officer of N.Y. Bancorp from 1990 to 1998. Assistant to the President of the United States from 1982 to 1985. Currently a director of LQ Corporation, Inc., American Home Mortgage Holdings, Inc. and A. Schulman Inc.
Dr. Singhvi is a recognized vaccine specialist, manufacturing expert and business leader in the pharmaceutical industry. Since assuming his current position, Dr. Singhvi has restructured Novavax to focus on product innovation and development, in particular influenza vaccine development using the company’s novel virus-like particle and Novasome technologies. Within six months of his appointment, Novavax’s market capitalization increased from $35 million to more than $300 million. Before joining Novavax, Dr. Singhvi headed vaccine manufacturing operations at Merck & Co., where increased production by 25 percent at the two plants he oversaw.
Dr. Singhvi received his M.S. and Sc.D. degrees in Chemical Engineering from the Massachusetts Institute of Technology. He also holds an M.B.A. from the Wharton School.
Dr. Rajiv I. Modi
Dr. Rajiv I. Modi, Managing Director, Cadila Pharmaceuticals is a Ph.D. in Biological Science from the University of Michigan, Ann Arbor, USA. He obtained his M.Sc. in Biochemical Engineering from Indian Institute of Technology (IIT), Bombay, India.
Dr. Modi is the winner of the Genetic Society of America's Best Scientific Poster at the International Genetics Congress held in August 1988 by the Genetic Society of America.
Dr. Modi has presented many papers on various aspects of Chemical Engineering, Biochemical Engineering and Biotechnology at many institutes in India and abroad. He was the invited speaker and participant at the Gordan Research Microbial Evolution and Population Biology in July 1989 at Plymouth State College, New Hampshire, USA.
Dr. Modi is a member of many prestigious organizations and associations.
James F. Young, Ph.D.
Dr. Young has over 30 years experience in the fields of molecular gentics, microbiology, immunology and pharmceutical development. He was previously President of Research and Development, including responsibility for regulatory affairs, at MedImmune where he was instrumental in the development of FluMist® and Synagis®. In 2005, Dr. Young was awarded the Albert B. Sabin Humanitarian Award. Prior to MedImmune, Dr. Young was influential in building the department of molecular genetics at Smith Kline & French Laboratories (now part of GlaxoSmithKline) and culminated as director, department of molecular genetics.
Prior to GlaxoSmithKline, Dr. Young was on the faculty of the department of microbiology at Mount Sinai School of Medicine in New York, NY. Dr. Young received his doctorate in microbiology and immunology from Baylor College of Medicine in Houston, Texas and Bachelor of Science degrees in biology and general sciences from Villanova University.
Dr. Douglas has over 25 years of biotechnology experience having served in Corporate Development roles at Genzyme Corporation since 1989. He is currently Senior Vice President Corporate Development and a Corporate Officer of Genzyme Corporation. As a leader of Genzyme’s Corporate Development team, Dr. Douglas has been involved in numerous acquisitions, licenses, joint ventures and strategic alliances. From 1982 till its merger with Genzyme Corporation in 1989, Dr. Douglas served in Science and Corporate Development capacities at Integrated Genetics.
Dr. Douglas was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology. He received a Ph.D. from the University of California, Berkeley in biochemistry and a B.S. in chemistry from the University of Michigan. He currently serves on the University of Michigan Technology Transfer National Advisory Board.